NCT06524167Recruiting
RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer
A Real-world Study of Adjuvant Radiotherapy in High Recurrence Risk Locally Advanced Thyroid Cancer
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
This study is a real-world study to observe the role of adjuvant radiotherapy in locally advanced recurrent high-risk thyroid cancer. The study included thyroid cancer that requires adjuvant radiotherapy to increase local control rate, excluding undifferentiated cancer. Local-regional recurrence free survival is the primary endpoint of the study.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 23 Jul 2024
- Start date
- 2 Jul 2024
- Primary completion date
- 30 Jun 2031
- Lead sponsor
- Fudan University
- Diseases
- Thyroid cancer, Childhood cancers
- NCT number
- NCT06524167
What you commit to
- Study type: Observational
- Planned participants: 80
- From 2 Jul 2024 to the primary completion date, 30 Jun 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously received radiation therapy for the head and neck area;
- Individuals with claustrophobia who are unable to undergo radiation therapy;
Other illness
- Untreated thyroid cancer or thyroid cancer that has only undergone surgical biopsy;
- Within 5 years or simultaneously suffering from other active malignant tumors. Cured local tumors, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, can be included in the group;
- There are other physical illnesses that affect patients' ability to receive standard treatment;
Lab values
- According to the researcher's judgment, there may be other factors that could force the subject to terminate the study midway, such as suffering from other serious illnesses (including mental illnesses) that require concurrent treatment, severe abnormal laboratory test values, family or social factors that may affect the subject's safety or the collection of trial data;
Other
- Pregnant or lactating women;
- Other patients deemed unsuitable for inclusion by the treating physician.
Who the study is looking for
- Patients voluntarily join this study and sign an informed consent form;
- Age: ≥ 14 years old,\<80 years old, male or female not limited;
- Thyroid cancer diagnosed by histopathology, including differentiated thyroid cancer, medullary carcinoma, poorly differentiated carcinoma, etc;
- High risk of local late recurrence, meeting any of the following criteria:
- The surgery did not achieve R0 resection;
- After neoadjuvant therapy;
- Pathological types with poor prognosis, such as poorly differentiated cancer, CASTLE, etc;
- Thyroid cancer with obvious extracapsular invasion, invading important structures such as the esophagus, trachea, and recurrent laryngeal nerve, requiring adjuvant radiotherapy;
- For patients with distant metastasis, researchers need to determine the value of local treatment;
- The main organ functions are normal;
- Good compliance and cooperation with follow-up.
Age in the registry: 14 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.